Agios Pharmaceuticals | AGIO - Assets

Stock Price
28.17
Daily Change
-0.56 -1.95%
Monthly
-19.33%
Yearly
-3.46%
Q2 Forecast
27.60

Agios Pharmaceuticals reported $1.18B in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
AbbVie USD 136.46B 2.5B Mar/2026
Agios Pharmaceuticals USD 1.18B 112.24M Mar/2026
Alnylam Pharmaceuticals USD 5.13B 163.22M Mar/2026
Amgen USD 92.5B 1.92B Mar/2026
Arrowhead Research USD 2.27B 664.08M Mar/2026
Astellas Pharma JPY 3.57T 36.87B Mar/2026
AstraZeneca USD 114.02B 59M Mar/2026
Bayer EUR 107.94B 3.4B Mar/2026
Biogen USD 29.48B 43.6M Mar/2026
BioMarin Pharmaceutical USD 8.59B 996.99M Mar/2026
Bristol-Myers Squibb USD 86.48B 3.56B Mar/2026
Daiichi Sankyo JPY 3.82T 252.52B Dec/2025
Eli Lilly USD 116.58B 4.1B Mar/2026
Exelixis USD 2.59B 250.83M Mar/2026
Gilead Sciences USD 56.28B 2.74B Mar/2026
GlaxoSmithKline GBP 62.87B 1.75B Mar/2026
Incyte USD 7.34B 381.14M Mar/2026
Ionis Pharmaceuticals USD 3.45B 74M Mar/2026
Merck USD 128.68B 8.18B Mar/2026
Moderna USD 11.49B 850M Mar/2026
Nektar Therapeutics USD 280.41M 20.94M Dec/2025
Novartis USD 118.53B 7.58B Mar/2026
Novartis USD 110.95B 3.66B Dec/2025
Pfizer USD 207.62B 542M Mar/2026
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Regeneron Pharmaceuticals USD 40.87B 310.1M Mar/2026
Roche Holding CHF 100.7B 5.94B Dec/2025
Sarepta Therapeutics USD 3.18B 170.77M Mar/2026
Vertex Pharmaceuticals USD 26.48B 841.4M Mar/2026